Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 406 participants.

Also called NCT02477865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 406 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02477865
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02477865. Randomized; triple masking; primary purpose treatment. Start 2014-03-23 (actual); primary completion 2016-05-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
PEX168(100µg)
Intervention (Drug)
PEX168(200µg)
Intervention (Drug)
Placebo
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02477865
Content hash
ea96e9189465d0ad2591838a8e01544c9a767f018bab9b0f9e620ab37cc234a3